NICE says why eye to Ozdurex and Eylea for DME
This article was originally published in Scrip
In two separate pieces of final and binding guidance, NICE has recommended Bayer's Eylea (aflibercept) and Allergan's Ozurdex (dexamethasone intravitreal implant) for treating NHS patients with diabetic macular edema. Both sets of recommendations come with restrictions: Eylea can be used if the eye has a central retinal thickness of 400 micrometres or more at the start of treatment, and if Bayer provides the drug at a discount as agreed in a confidential patient access scheme. Meanwhile, Ozurdex is to be used in patients if the implant is to be used in an eye with an intraocular (pseudophakic) lens and if non-corticosteroid treatment is unsuitable or ineffective. Both drugs will compete against Roche's Lucentis (ranibizumab) and off-label Avastin. NICE first put its guidance out for consultation in February.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.